Abstract

Recent studies have shown that inflammatory markers like C-reactive protein (CRP) predicts futurerisk of diabetes mellitus (DM), and the data about the relationship between inflammation and the roleof cyclooxygenase (COX) enzyme with type 2 DM are scar. In the present study, the clinical use ofCOX-inhibitors to improve glycemic state in type 2, poorly controlled DM patients was tested. Thirtyeight(38) type 2 diabetic patients (12 males and 26 females) with age range of 55±S.E.1.25yrs., whoare maintained on hypoglycemic agents for 6.5±S.E.0.92 years, but with poor glycemic control, wereincluded in the study and randomly allocated into 3 groups; first group was treated with 25mg/dayrofecoxib and the second was treated with 100 mg/day diclofenac for 2 months. The third groupserved as control for comparison. Fasting serum glucose (FSG), glycated hemoglobin (HbA1c), CRPand body mass index (BMI) were evaluated pre- and post-treatment. All the poorly controlled type2DM patients included in the study were presented with high CRP levels. Treatment with rofecoxiband diclofenac for 60 days, showed relatively non-significant decrease in CRP, and did not produceany significant improvement in glycemic control. It could be concluded that COX pathway may not bethe major contributor to the inflammatory events associated with DM and its associated complications.Further extensive pharmacologically based evaluation in this respect was necessary.

The article was added to IASJ on 2012-05-22

290 Total full text downloads since the date of addition